Steering group member of the Skin Surgery Research Collaborative, UK

The aim of a priority setting partnership (PSP) is to identify what areas of research are important to patients, families, carers and clinicians. PSPs use a tried and tested method which has been developed by James Lind Alliance (JLA). This enables patients, carers and clinicians to come together on an equal footing to develop a ‘Top 10’ list of unanswered research questions or topics. The scope of this PSP is quite broad as it includes all surgical treatments for all types of skin cancer. The steering group therefore decided it will aim to identify a “Top 10” for primary skin cancer surgery (i.e. the first presentation of a skin cancer) and a “Top 10” for surgical treatment of local or regional recurrence of skin cancer (i.e. when it comes back near the scar site or in the nearby lymph glands). See link.

Eyelid melanoma in the UK 

I am the Chief investigator for a nationwide prospective epidemiological study on eyelid melanoma (a NIHR Portfolio registered study) in conjunction with the British Ophthalmology Surveillance Unit (BOSU). The specific aims of the prospective study over 5 years is to; (1) Establish the incidence of eyelid melanoma in the UK, (2) Determine the patient demographics including ethnicity, age, gender, laterality, risk factors, histological subtype, postcode and source of referral,
(3) Characterise the clinical presentation of eyelid melanoma including any genomic analysis such as BRAF status in relation to the histological subtype, (4) Identify the excision margin used in the removal of eyelid melanoma and re-excision rate, (5) Identify current mode of treatment for nodal positive eyelid melanoma such as the use of biologics and targeted therapy, and (6) Establish the visual outcome and disease progression at 12 months and 5 years

2020 Co-lead of COVID-19 studies during the pandemic at Kings College Hospital South Sites  

Observational studies include COV-PALL, IMET, GEnOMICC, ISARIC, SOAP, SIREN and PAN COVID.

2020 Blizard Institute collaboration Mutational drivers in Eyelid Basal Cell Carcinoma

I am investigating the role of the mutational drivers FLNB and HECTD4 in periocular morphoeic BCC. The aims; (1) To compare and contrast the expression of FLNB and HECTD4 in periocular mBCC with expression in both periocular nodular BCC and epidermal mBCC and nBCC, (2) Investigate the effects of FLNB and HECTD4 knockdown in human keratinocytes in relation to cell migration, invasion, proliferation and apoptosis, and (3) Investigate the impact of FLNB and HECTD4 knockdown in a keratinocyte cell made null for PTCH (see methodology and background) and in response to Gli2 overexpression in keratinocytes.


  1. Bladen JC, Mombaerts I, Kakizaki H, McNab AA, Norris JH, Verity D, DeAngelis DD, Ataullah SM, McCormick AG, Parkin B, Patel BCK, Morley AMS, Rose GE, Malhotra R. Diplopia Following the Insertion of a Canalicular Bypass Tube: Etiology, Risk Factors, Management, and Outcomes. Ophthalmic Plast Reconstr Surg. 2020. Epub 2020/10/04. doi: 10.1097/IOP.0000000000001770. PubMed PMID: 33009327.
  2. Bladen JC, Siah WF, Tan P, Litwin AS, Ali S, Malhotra R. Peri-orbital surgical emphysema following endoscopic dacryocystorhinostomy. J Laryngol Otol. 2020:1-3. Epub 2020/09/22. doi: 10.1017/S0022215120001875. PubMed PMID: 32951613.
  3. Bladen JC, Favor M, Litwin A, Malhotra R. Switchover study of onabotulinumtoxinA to incobotulinumtoxinA for facial dystonia. Clin Exp Ophthalmol. 2020. Epub 2020/07/28. doi: 10.1111/ceo.13829. PubMed PMID: 32710447.
  4. Nigam C, Bladen JC. Re: Peri-operative management of ophthalmic patients on anti-thrombotic agents: a literature review. Eye (London). 2020. Epub 2020/06/17. doi: 10.1038/s41433-020-1014-x. PubMed PMID: 32541888.
  5. Bladen JC, Malhotra R. Reporting outcomes of hyaluronic gel filler as a treatment for epiblepharon. Graefes Arch Clin Exp Ophthalmol. 2019;257(12):2769-73. Epub 2019/10/24. doi: 10.1007/s00417-019-04479-9. PubMed PMID: 31641882.
  6. Bladen JC, Feldman I, Favor M, Dizon M, Litwin A, Malhotra R. Long-term outcome of flexible onabotulinum toxin A treatment in facial dystonia. Eye (London). 2019;33(3):349-52. Epub 2018/09/12. doi: 10.1038/s41433-018-0203-3. PubMed PMID: 30202071; PubMed Central PMCID: PMCPMC6460690.
  7. Bladen JC, Cascone N, Pearson AR, Litwin A, Malhotra R. Dry eye after Lester Jones tube insertion for epiphora. Orbit. 2019;38(5):357-61. Epub 2018/12/14. doi: 10.1080/01676830.2018.1552710. PubMed PMID: 30522385.
  8. Bladen JC, Wang J, Sangaralingam A, Moosajee M, Fitchett C, Chelala C, et al. MicroRNA and transcriptome analysis in periocular Sebaceous Gland Carcinoma. Sci Rep. 2018;8(1):7531. Epub 2018/05/16. doi: 10.1038/s41598-018-25900-z. PubMed PMID: 29760516; PubMed Central PMCID: PMCPMC5951834.
  9. Bladen JC, Moosajee M, Tracey-White D, Beaconsfield M, O’Toole EA, Philpott MP. Analysis of hedgehog signaling in periocular sebaceous carcinoma. Graefes Arch Clin Exp Ophthalmol. 2018. Epub 2018/02/10. doi: 10.1007/s00417-018-3900-5. PubMed PMID: 29423837.
  10. Bladen JC, Gill JS, Miszkiel K, Ezra DG. Stroke-induced resolution of primary blepharospasm: evidence for the lenticular nucleus as a control candidate. BMJ case reports. 2018;2018. Epub 2018/07/28. doi: 10.1136/bcr-2018-224339. PubMed PMID: 30049673; PubMed Central PMCID: PMCPMC6067133.
  11. Minakaran N, Soorma T, Bladen JC, Moosajee M. Vision, eye disease, and art. Eye (London). 2016;30(12):1648. Epub 2016/07/30. doi: 10.1038/eye.2016.175. PubMed PMID: 27472204; PubMed Central PMCID: PMCPMC5177747.
  12. Bowes O, Pradeep A, Lim LT, Grant S, Dean WH, O’Gallagher M,  Idrees F, Hanspal I, Niyadurupola N; Ophthalmic Trainees’ Group of the Royal College of Ophthalmologists. The fate of ophthalmology trainees in the UK-CCT holders 2007 to 2010. Eye (London). 29. England2015. p. 445-6.
  13. Rodrigues IA, Bladen JC. Clinical Management: Are times about to change. British journal of healthcare management. 2013;19(3):133-5.
  14. O’Gallagher MK, Lewis G, Mercieca K, Moutray T, Ophthalmic Trainees’ Group of the Royal College of Ophthalmologists. The impact of the European Working Time Regulations on Ophthalmic Specialist Training–a national trainee survey. Int J Surg. 2013;11(9):837-40. Epub 2013/09/03. doi: 10.1016/j.ijsu.2013.08.007. PubMed PMID: 23994298.
  15. Bladen JC, Norris JH, Malhotra R. Indications and outcomes for revision of gold weight implants in upper eyelid loading. Br J Ophthalmol. 2012;96(4):485-9. Epub 2011/10/29. doi: 10.1136/bjophthalmol-2011-300732. PubMed PMID: 22034542.
  16. Bladen JC, Norris JH, Malhotra R. Cosmetic comparison of gold weight and platinum chain insertion in primary upper eyelid loading for lagophthalmos. Ophthal Plast Reconstr Surg. 2012;28(3):171-5. Epub 2012/03/31. doi: 10.1097/IOP.0b013e3182467bf7. PubMed PMID: 22460670.
  17. Bladen JC, Moosajee M, Tumuluri K, Olver JM. The use of a pleated strip of autogenous temporalis fascia graft for frontalis suspension in recurrent poor levator function ptosis in adult patients. Orbit. 2012;31(2):114-8. Epub 2012/04/12. doi: 10.3109/01676830.2011.648805. PubMed PMID: 22489854.
  18. Bladen JC, Moosajee M, Angunawela R, Roberts C. Transient internal ophthalmoplegia after inferior oblique myectomy. J AAPOS. 2009;13(6):596-7. Epub 2009/12/17. doi: 10.1016/j.jaapos.2009.09.011. PubMed PMID: 20006825.
  19. Bladen JC, Moosajee M, Renowden S, Carter M, Sainsbury C, Jardine P. Spontaneous intracranial hypotension in adolescence. BMJ case reports. 2009;2009:bcr2006096644. Epub 2009/01/01. doi: 10.1136/bcr.2006.096644. PubMed PMID: 21687145; PubMed Central PMCID: PMCPMC3105870.
  20. Bladen JC, Moosajee M, Renowden S, Carter M, Sainsbury C, Jardine P. Neurological pictures. Spontaneous intracranial hypotension in adolescence. J Neurol Neurosurg Psychiatry. 2007;78(2):167. Epub 2006/07/13. doi: 10.1136/jnnp.2006.096644. PubMed PMID: 16835286; PubMed Central PMCID: PMCPMC2077665.
  21. Bladen JC, Moosajee M, Bassett JH. A tense case–Carney’s triad. J R Soc Med. 2004;97(11):540-1. Epub 2004/11/03. doi: 10.1258/jrsm.97.11.540. PubMed PMID: 15520151; PubMed Central PMCID: PMCPMC1079650.